Progress towards a clinically-successful ATR inhibitor for cancer therapy
作者： Robert A. Falconer , Paul M. Loadman , Francis M. Barnieh
DOI: 10.1016/J.CRPHAR.2021.100017
关键词:
摘要: … ATR inhibitors that have emerged in recent decades. The current applications of these inhibitors … the various concerns raised or observed with ATR inhibition in both the preclinical and …
sci-hub.st 参考文章(160)
Tuya Pal, Jenny Permuth-Wey, Judith A. Betts, Jeffrey P. Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A. Martino, Katie Wakeley, George Wilbanks, Santo Nicosia, Alan Cantor, Rebecca Sutphen, BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer. ,vol. 104, pp. 2807- 2816 ,(2005) , 10.1002/CNCR.21536
Qingsong Liu, Jinhua Wang, Seong A. Kang, Carson C. Thoreen, Wooyoung Hur, Tausif Ahmed, David M. Sabatini, Nathanael S. Gray, Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer Journal of Medicinal Chemistry. ,vol. 54, pp. 1473- 1480 ,(2011) , 10.1021/JM101520V
Simona Negrini, Vassilis G. Gorgoulis, Thanos D. Halazonetis, Genomic instability — an evolving hallmark of cancer Nature Reviews Molecular Cell Biology. ,vol. 11, pp. 220- 228 ,(2010) , 10.1038/NRM2858
Yosef Shiloh, Michael B. Kastan, ATM: Genome stability, neuronal development, and cancer cross paths Advances in Cancer Research. ,vol. 83, pp. 209- 254 ,(2001) , 10.1016/S0065-230X(01)83007-4
Nouf Alsubhi, Fiona Middleton, Tarek M.A. Abdel-Fatah, Peter Stephens, Rachel Doherty, Arvind Arora, Paul M. Moseley, Stephen Y.T. Chan, Mohammed A. Aleskandarany, Andrew R. Green, Emad A. Rakha, Ian O. Ellis, Stewart G. Martin, Nicola J. Curtin, Srinivasan Madhusudan, Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer Molecular Oncology. ,vol. 10, pp. 213- 223 ,(2016) , 10.1016/J.MOLONC.2015.09.009
Kevin M Foote, Alan Lau, J Willem M Nissink, Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer Future Medicinal Chemistry. ,vol. 7, pp. 873- 891 ,(2015) , 10.4155/FMC.15.33
Karlene A. Cimprich, David Cortez, ATR: an essential regulator of genome integrity Nature Reviews Molecular Cell Biology. ,vol. 9, pp. 616- 627 ,(2008) , 10.1038/NRM2450
William R Taylor, George R Stark, Regulation of the G2/M transition by p53 Oncogene. ,vol. 20, pp. 1803- 1815 ,(2001) , 10.1038/SJ.ONC.1204252
E Levy-Lahad, E Friedman, Cancer risks among BRCA1 and BRCA2 mutation carriers British Journal of Cancer. ,vol. 96, pp. 11- 15 ,(2007) , 10.1038/SJ.BJC.6603535
Mark O'Driscoll, Victor L. Ruiz-Perez, C. Geoffrey Woods, Penny A. Jeggo, Judith A. Goodship, A splicing mutation affecting expression of ataxia–telangiectasia and Rad3–related protein (ATR) results in Seckel syndrome Nature Genetics. ,vol. 33, pp. 497- 501 ,(2003) , 10.1038/NG1129